Mean Interglomerular Area Measurement for FSGS Subtype Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for distinguishing primary Focal segmental glomerulosclerosis (FSGS) from maladaptive FSGS rely heavily on medical intuition and unspecific information, often leading to inappropriate immunosuppressive treatment in patients who do not require it.
Innovation Solution
A method involving the determination of mean interglomerular area (MIA) in renal biopsies, using high-definition whole slide images, which correlates with glomerular filtration rate and proteinuria levels to estimate the probability of maladaptive glomerular impairment, thereby differentiating between primary and maladaptive FSGS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If medical intuition and unspecific information are used to distinguish primary FSGS from maladaptive FSGS, then the diagnosis can be made, but the accuracy is low and leads to inappropriate immunosuppressive treatment
Solution Approach 1:
The patent replaces medical intuition and subjective assessment with objective morphometric measurement. By using image analysis to quantify the mean interglomerular area (MIA), the system substitutes human expertise with a measurable, reproducible parameter that objectively distinguishes between primary and maladaptive FSGS subtypes, thereby improving diagnostic accuracy and reducing treatment errors.
Solution Approach 2:
The patent introduces a new quantitative parameter (mean interglomerular area) that changes the diagnostic approach from qualitative assessment to quantitative measurement. This parameter provides specific, objective information about glomerular architecture that was previously unavailable, enabling accurate differentiation between FSGS subtypes and guiding appropriate treatment decisions.
2Productivity
If immunosuppressive agents are prescribed based on probability estimation, then treatment can be initiated, but unnecessary treatment is administered to patients who do not require it
Solution Approach 1:
The patent implements a feedback mechanism where the MIA measurement provides objective evidence that feeds back into the treatment decision-making process. This feedback allows clinicians to accurately identify which patients truly have primary FSGS and require immunosuppressive therapy, versus those with maladaptive FSGS who do not, thereby preventing unnecessary treatment while maintaining appropriate care for those who need it.
3Measurement precision
If the mean interglomerular area is measured in renal biopsies, then accurate differentiation between FSGS subtypes is achieved, but the complexity of the diagnostic process increases
Solution Approach 1:
The patent extracts the essential diagnostic information from the complex renal biopsy image by focusing on a single key parameter: the mean interglomerular area. By isolating this specific morphometric feature, the system simplifies the diagnostic process while maintaining high accuracy, avoiding the need to analyze every detail of the biopsy while still achieving reliable subtype differentiation.
Data Source
AI summary
An observational cohort with 40 patients (20 patients with primary FSGS and maladaptive FSGS, respectively) was carried out to identify renal morphometric parameters of interest. In addition, a validation cohort with 40 patients (20 patients with primary FSGS and maladaptive FSGS, respectively) was established to confirm the results matching age. estimated glomerular filtration rate (eGFR), and level of proteinuria. In the observational cohort, they found that the mean interglomerular area (MIA), a marker of glomerular scarcity described in the table 2) was significantly lower in patients with primary FSGS compared to maladaptive FSGS 90 [76-100] vs. 198 [165-299]μm2. p<0.0001. This finding was confirmed in the validation cohort 133 [109-159] vs. 204 [170-339]μm2 (p=0.0017). The present invention relates to a method for estimating the probability of maladaptive glomerular impairment in a subject comprising the following steps: i) obtaining a biological sample from said subject: ii) determining mean interglomerular area (MIA) value and iii) concluding that the subject has a high probability of maladaptive glomerular impairment when the MIA value is higher than the reference value: or concluding that the subject is not likely to have maladaptive glomerular impairment when the MIA value is lower than the reference value.